Editorial Archives - Page 2 of 19 - Revista Brasileira de Ginecologia e Obstetrícia

In addition to causing relevant changes in the global routine, the COVID-19 pandemic status announced and recognized by the World Health Organization (WHO) on March 11, 2020, made it clear that no country was ready to face an infectious disease that spread rapidly and involved objective risk of death. The retrospective assessment of the sequence […]

Gestational trophoblastic neoplasia (GTN) is a rare tumor that arises from placental tissues and exhibits a high cure rate when treated with cytotoxic chemotherapy. Although its most common origin is hydatidiform mole, GTN can develop from any type of pregnancy: abortion, ectopic pregnancy, or preterm/term gestation. The early diagnosis of GTN is the key to […]

Individual Feedback to Candidates Feedback on the results of each candidate’s performance in the IPT-GO is provided confidentially through a password-protected online system with personal access. The aim of this measure is to avoid embarrassment, discrimination or disqualification of candidates with unsatisfactory performance. Therefore, this evaluation is not intended to rank candidates or services. The […]

Reproductive choice and access to contraception are basic rights for all women, representing a major step forward in the improvement of gender equality. Sexual and reproductive health is paramount when considering public health, and has been directly affected by the COVID-19 pandemic, since these services suffered a reduction in their capacity for elective care, including […]

Medical Residency Programs (MRPs) have been presented as the dominant model for postgraduate medical training worldwide. They are considered the gold standard by the medical community and give different status to doctors who hold these titles. The success of this model resides in the link established between theoretical learning and the practice experienced in health […]

On January 17, 2021, two vaccines were approved by ANVISA for emergency use to help combat COVID-19: Coronavac and Covishield/Oxford. The first vaccine is composed of inactivated (killed) viruses, was produced by the Chinese company Sinovac and in Brazil, will be produced by the Butantã Institute (São Paulo). The second is an adenovirus non-replicating viral […]

At the 73rd General Assembly, in 2020, the World Health Organization (WHO) approved the adoption of the “Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem,” based on the guarantee of the three following pillars: 1) that 90% of girls up to 15 years of age receive the vaccine against […]